@article{00f599a9ee29432d9851afd40ab7c06d,
title = "Ovarian cancer treatment stratification using ex vivo drug sensitivity testing",
abstract = "Background: Treatment options for patients with platinum-resistant ovarian cancer are generally palliative in nature and rarely have realistic potential to be curative. Because many patients with recurrent ovarian cancer receive aggressive chemotherapy for prolonged periods, sometimes continuously, therapy-related toxicities are a major factor in treatment decisions. The use of ex vivo drug sensitivity screens has the potential to improve the treatment of patients with platinum-resistant ovarian cancer by providing personalized treatment plans and thus reducing toxicity from unproductive therapy attempts. Materials and Methods: We evaluated the treatment responses of a set of six early-passage patient-derived ovarian cancer cell lines towards a set of 30 Food and Drug Administration-approved chemotherapy drugs using drug-sensitivity testing.",
keywords = "Ex vivo drug sensitivity screening, Ovarian cancer, Precision medicine",
author = "Ines Lohse and Azzam, {Diana J.} and Hassan Al-Ali and Volmar, {Claude Henry} and Brothers, {Shaun P.} and Ince, {Tan A.} and Claes Wahlestedt",
note = "Funding Information: Some of this work was supported by the Sylvester Cancer Center Molecular Therapeutics Shared Resource (MTSR). Funding Information: SB received support from the National Institutes of Health (R01NS092671 and R01MH110441) and the Jay Weiss Institute for Health Equity. CW{\textquoteright}s laboratory is currently funded by NIH grants DA035592, DA035055 and AA023781, and Florida Department of Health grants 6AZ08 and 7AZ26. HAA received support from the National Institutes of Health (NS100531) and the Wallace H. Coulter Foundation. TAI is supported by grants from Breast Cancer Research Foundation (BCRF), NCI (R33CA214310) and Department of Defense (DoD) Ovarian Cancer Research Program (OCRP) grant (OC130649). Publisher Copyright: {\textcopyright} 2019 International Institute of Anticancer Research. All rights reserved.",
year = "2019",
doi = "10.21873/anticanres.13558",
language = "English (US)",
volume = "39",
pages = "4023--4030",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",
}